Tuesday, November 29, 2016

BRIEF-ARIAD announces FDA full approval and label update for Iclusig (ponatinib)

* ARIAD announces FDA full approval and label update for

Iclusig (ponatinib) based on long-term efficacy and safety data

from Phase 2 PACE clinical trial

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)